ArticleTransactions of the Royal Society of Tropical Medicine and Hygiene2021
Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination.
Article in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Stopping azithromycin mass drug administration for trachoma: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Prevalence of Ocular Chlamydia trachomatis Infection in Amhara Region, Ethiopia, after 8 Years of Trachoma Control Interventions.The American journal of tropical medicine and hygiene · 2023Trial
- Prevalence of Ocular Chlamydia trachomatis and Active Trachoma among Children in Merhabete District, Amhara, Ethiopia.The American journal of tropical medicine and hygiene · 2025Article
- Progress towards the elimination of trachoma as a public health problem in four counties of Eastern Equatoria State, Republic of South Sudan.Tropical medicine & international health : TM & IH · 2025Article
- Article
- The Epidemiology of Ocular Chlamydia trachomatis Infection within Districts Persistently Endemic for Trachoma in Amhara, Ethiopia.The American journal of tropical medicine and hygiene · 2024Article
- Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- District-Level Forecast of Achieving Trachoma Elimination as a Public Health Problem By 2030: An Ensemble Modelling Approach.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Modelling morbidity for neglected tropical diseases: the long and winding road from cumulative exposure to long-term pathology.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- Scoping review of modelling studies assessing the impact of disruptions to essential health services during COVID-19.BMJ open · 2023Article
- A Virtual Reading Center Model Using Crowdsourcing to Grade Photographs for Trachoma: Validation Study.Journal of medical Internet research · 2023Article
- Cost and community acceptability of enhanced antibiotic distribution approaches for trachoma in the Republic of South Sudan: enhancing the A in SAFE (ETAS) study protocol.BMC ophthalmology · 2023Article
- Modeling the "F" in "SAFE": The dynamic game of facial cleanliness in trachoma prevention.PloS one · 2023Article
- Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study.The Lancet. Global health · 2022Article
- Trachoma.Nature reviews. Disease primers · 2022Review
- Evaluating the potential impact of interruptions to neglected tropical disease programmes due to COVID-19.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- How modelling can help steer the course set by the World Health Organization 2021-2030 roadmap on neglected tropical diseases.Gates open research · 2021Article
- Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance.Advances in parasitology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe COVID-19 pandemic has disrupted planned annual antibiotic mass drug administration (MDA) activities that have formed the cornerstone of the largely successful global efforts to eliminate trachoma as a public health problem.
methodsUsing a mathematical model we investigate the impact of interruption to MDA in trachoma-endemic settings. We evaluate potential measures to mitigate this impact and consider alternative strategies for accelerating progress in those areas where the trachoma elimination targets may not be achievable otherwise.
resultsWe demonstrate that for districts that were hyperendemic at baseline, or where the trachoma elimination thresholds have not already been achieved after three rounds of MDA, the interruption to planned MDA could lead to a delay to reaching elimination targets greater than the duration of interruption. We also show that an additional round of MDA in the year following MDA resumption could effectively mitigate this delay. For districts where the probability of elimination under annual MDA was already very low, we demonstrate that more intensive MDA schedules are needed to achieve agreed targets.
conclusionThrough appropriate use of additional MDA, the impact of COVID-19 in terms of delay to reaching trachoma elimination targets can be effectively mitigated. Additionally, more frequent MDA may accelerate progress towards 2030 goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.